Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Linc AB is a Stockholm-based investment company founded in 1991, primarily focused on the Nordic Life Science industry. The firm has evolved significantly under the leadership of Bengt Julander, who has over 40 years of experience in pharmaceuticals. Linc aims to develop well-managed, product-oriented companies, particularly in pharmaceuticals and medical technology. The company engages in investments across both private and public sectors, typically at early stages for pharmaceuticals and later stages for medical technology.
As of now, Linc manages assets totaling approximately SEK 4.7 billion (around $500 million) and has a portfolio that includes 20 companies. The firm operates as a publicly listed investment company on Nasdaq Stockholm, having completed its IPO in Q2 2021, raising approximately SEK 1.2 billion ($142 million). Linc's strategic focus on the Nordic region allows it to leverage local expertise while also considering international opportunities.
Linc AB invests in product-oriented companies within the Nordic Life Science sector, specifically targeting pharmaceuticals and medical technology. The firm typically invests between 25 to 250 million SEK (approximately $2.5 million to $25 million) across various funding stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity. Initial investments are often smaller, followed by larger subsequent investments as companies progress.
The firm seeks to be one of the larger investors in the companies it supports, ensuring a substantial impact on their growth and development. Linc's investment strategy emphasizes a long-term, active-owner model, focusing on small- and mid-cap life-science companies with global potential. This approach allows Linc to provide not only capital but also strategic guidance and expertise in navigating the complexities of the pharmaceuticals and medical technology industries.
Linc AB's portfolio consists of 20 companies, showcasing a diverse range of investments in the life science sector. Notable companies include:
Additionally, Linc has achieved notable exits, including the acquisition of Calliditas Therapeutics by Asahi Kasei in May 2024 for SEK 11.2 billion, marking a significant milestone in the firm's investment history.
Bengt Julander: Chairman of the Board and founder of Linc AB, Bengt has over 40 years of experience in the pharmaceuticals industry. He is the public face of the firm and has been instrumental in its strategic direction.
Karl Tobieson: CEO of Linc AB, Karl oversees the firm's operations and investment strategies. His leadership is pivotal in guiding the firm’s focus on the Nordic Life Science sector.
Thomas Bergh: CFO of Linc AB, Thomas manages the financial aspects of the firm, ensuring sound fiscal practices and investment management.
Anders Hansen: Board Member, Anders brings additional expertise to the board, contributing to the strategic oversight of the firm’s investments.
To pitch Linc AB, founders should send an email to karl.tobieson@linc.se. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. Linc prefers detailed information about the product and its potential impact on the healthcare sector.
Response times can vary, but founders should expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory. Linc values clarity and thoroughness in pitches, so founders should ensure that all relevant information is included to facilitate the evaluation process.
In May 2024, Linc AB achieved a significant exit with the acquisition of Calliditas Therapeutics by Asahi Kasei for SEK 11.2 billion. This marked a notable milestone for Linc's portfolio and highlighted the firm's successful investment strategy.
As of late 2024, Linc continues to manage a diverse portfolio of 20 companies, focusing on the Nordic Life Science sector. The firm remains active in seeking new investment opportunities within pharmaceuticals and medical technology.
What are Linc AB's investment criteria?
Linc AB focuses on product-oriented companies within the Nordic Life Science sector, particularly in pharmaceuticals and medical technology. The firm typically invests between 25 to 250 million SEK, targeting early-stage investments for pharmaceuticals and later-stage investments for medical technology.
How can I pitch to Linc AB?
What makes Linc AB different from other investors?
Linc AB distinguishes itself by being a significant investor in its portfolio companies, providing not only capital but also strategic guidance and expertise in the life science sector. The firm adopts a long-term, active-owner model, which allows it to influence the growth and development of its investments.
What is Linc AB's geographic focus?
The firm primarily focuses on the Nordic region, investing in companies that operate within the life science sector. However, Linc also considers international opportunities for its portfolio companies.
What is Linc AB's post-investment involvement?
Linc AB engages in active ownership and provides strategic guidance to its portfolio companies. This involvement includes mentorship, operational support, and assistance in navigating the complexities of the pharmaceuticals and medical technology industries.
What is the typical check size for Linc AB?
Linc AB typically invests between 25 to 250 million SEK (approximately $2.5 million to $25 million) in its portfolio companies, depending on the stage and needs of the business.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.